Kardigan Debuts with $300M and Visionary Team to Revolutionize Cardiovascular Medicine Through Personalized Therapies

San Francisco & Princeton, NJ, January 10, 2025 (Business Wire) -- Kardigan launches with $300 million in funding and a mission to cure and prevent cardiovascular disease, led by Tassos Gianakakos and an expert team of former MyoKardia executives. The company’s proprietary cardiac intelligence model aims to personalize treatments, increase clinical efficiency, and accelerate drug development. With a portfolio of late-stage programs, Kardigan is positioned to address critical treatment gaps in cardiovascular medicine.

Read full article here.